Compare Suncor Energy Inc. (SU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs BIO-TECHNE Corp — how do they compare? Suncor Energy Inc. trades at $70.57 (market cap $80.03B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Suncor Energy Inc. is far larger — about 7× BIO-TECHNE Corp's market cap, and Suncor Energy Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and BIO-TECHNE Corp for 63 Days on average.
| SU | TECH | |
|---|---|---|
Market Cap | $80.03B | $11.37B |
Volume | 2,907,827 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $71.87 | $72.61 |
52-Week Low | $38.17 | $43.31 |
Typical Hold Time | 57 Days | 63 Days |
Enterprise Value | $86.58B | $11.40B |
Dividend Yield | 2.49% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $70.91, up 3.94% today, reflecting strong momentum near recent highs. The stock exhibits a bullish technical trend with support at $68 and resistance at $69. Fundamentally, SU maintains solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 12.98. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Cash flow remains robust, supporting shareholder returns via buybacks.
The outlook for SU is positive, driven by strong cash generation, debt reduction, and strategic asset sales. Investment appeal lies in its integrated model, shareholder returns, and exposure to global energy markets. Key risks include commodity price volatility, operational disruptions from weather, and execution of leadership transition. Analyst consensus is strongly bullish with 74% buy ratings, signaling confidence in continued performance.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
